左氧氟沙星序贯疗法治疗老年人下呼吸道细菌感染的效果分析  

Cost-effectiveness Analysis of Sequential Therapy of Levofloxacin Hydrochloride for Bacterial infection of Lower Respitatory Tract

作　　者：颜海弟 

机构地区：[1]湛江市第二人民医院,广东湛江524003

出　　处：《实用医技杂志》2007年第16期2122-2124,共3页Journal of Practical Medical Techniques

摘　　要：目的:评价盐酸左氧氟沙星序贯疗法治疗老年人下呼吸道细菌感染的临床疗效和经济效果。方法:78例下呼吸道细菌性感染老年患者随机分为两组,序贯组(A组)42例,采用盐酸左氧氟沙星500mg/d,静脉滴注2d^4d,继之以盐酸左氧氟沙星胶囊500mg/d,口服5d^10d;对照组(B组)36例,采用盐酸左氧氟沙星500mg/d,静脉滴注,疗程7d^14d。治疗结束后进行成本-效果分析。结果:A、B两组痊愈率分别为50.0%和52.8%,有效率分别为85.7%和83.3%,细菌清除率分别为84.8%和83.9%,不良反应发生率分别为4.8%和2.8%;经统计学比较,两组疗效相似(P>005),但A组的成本-效果比低于B组。结论:盐酸左氧氟沙星序贯疗法与单纯静脉滴注治疗相比,两者临床疗效相似,但前者显著降低了总医疗费用,值得临床应用推广。Objective To evaluate clinical therapeutic effect and economic effects of sequential therapy of levofloxacin hydrochloride for bacterial infection of Lower respitatory tract（LRT）. Methods 78 cases with bacterial infection of LRT were randomly divided into two groups. 43 cases in sequential group（ group A ）were treated with IV injection of levofloxacin hydrochloride 500 mg/d for 2 days - 4 days, then took levofloxacin hydrochloride capsules 500 mg/d for 5 days - 10 days ;36 cases in control group（ group B） were treated with IV injection of levofloxacin hydrochloride 500 mg/d for 7 days -14 days. Cost-effectiveness analysis were made after ending the treatment. Results The healing rate of group A and group B was respectively 50.0% and 52.8% ;the effective rate was respectively 85.7% and 83.3% ; bacteria clearance rate was respectively 84.8% and 83.9% ;the incidence rate of adverse reactions was respectively 4.8% and 2.8%. By statistical comparison, therapeutic effect between the two group was simila （P 〉 O. 05 ）, but cost-effectiveness ratio in group A was lower than that in group B. Conclusion Comparison between sequential therapy of levofloxacin hydrochloride and simple IV injection is found to be similar in clinical theraoutic effect.but the former obviously decreases total medical cost,so it is worthy to be spread in the clinic.

关 键 词：下呼吸道细菌感染 盐酸左氧氟沙星 序贯疗法 效果分析 

分 类 号：R56[医药卫生—呼吸系统]